Long-Term, Observational, Registry of Patients With Generalized Myasthenia Gravis Who Have Received Treatment With Complement C5 Inhibition Therapies

This long-term, observational registry focuses on patients with generalized myasthenia gravis (gMG) who have received treatment with complement C5 inhibition therapies. Managed under the COM, the project is conceived as a real-world, longitudinal data resource to capture clinical experiences, treatment patterns, and outcomes among people with gMG exposed to complement C5 inhibitors. By establishing a registry specifically centered on this therapeutic class and this disease population, the effort seeks to document the diverse trajectories of patients receiving these targeted therapies in routine clinical care, including demographic and baseline disease characteristics, concomitant treatments, reasons for initiating complement C5 inhibition, and subsequent clinical course.

The observational design emphasizes collection of data without intervention beyond usual clinical practice, making it well suited to reveal how complement C5 inhibitors are used across care settings and patient subgroups. Longitudinal follow-up is intended to allow assessment of durability of clinical responses, patterns of adherence and persistence, safety signals that emerge over extended exposure, and real-world effectiveness across heterogeneous patients who may have been underrepresented in controlled trials. The project places value on capturing context: comorbid conditions, prior therapies, dosing or administration variability, and concomitant management strategies that together shape outcomes in everyday practice.

Beyond individual patient trajectories, the registry aims to support analyses that inform clinicians, patients, and health systems about expected course and variability in response to complement C5 inhibition in generalized myasthenia gravis. Aggregated data can help characterize the spectrum of treatment responses and identify subgroups with differential benefit or risk. The resource is also intended to serve as a foundation for hypothesis generation and for designing future studies, whether observational or interventional, by highlighting areas of unmet need and gaps in evidence. By compiling standardized, longitudinal data across multiple sites and care environments, the registry aspires to enhance understanding of long-term safety and effectiveness outside strictly controlled trial conditions.

As a long-term observational registry, data governance, consistent data capture and stewardship are emphasized to maximize data quality and utility while respecting patient privacy. The project under COM oversight focuses on structured collection of core clinical variables related to diagnosis, treatment exposure to complement C5 inhibitors, clinical outcomes, and relevant patient-reported experiences when available. Ultimately, the this work is intended to be a practical, clinic-informed repository that complements existing clinical trial evidence and supports better-informed clinical decision-making for people with generalized myasthenia gravis considering or receiving complement C5 inhibition therapies. The effort emphasizes transparency about its observational scope and aims to provide a sustained, accessible source of real-world evidence to illuminate long-term patterns of use and outcomes in this specific therapeutic context.